Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
- Publication Information:
Original Publication: Chicago, Il : American Medical Association, [2015]-
- Subject Terms:
- Abstract:
Importance: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti-epidermal growth factor receptor-based regimen might be efficacious. Recent data suggest the role of liquid biopsy as a tool to track molecular events in circulating tumor DNA (ctDNA).
Objective: To prospectively assess the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type mCRC who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy.
Design, Setting, and Participants: Multicenter phase 2 single-arm trial conducted from January 7, 2015, to June 19, 2017. Liquid biopsies for analysis of ctDNA were collected at baseline. Main eligibility criteria included RAS and BRAF wild-type status on tissue samples; prior first-line irinotecan- and cetuximab-based regimen with at least partial response, progression-free survival of at least 6 months with first-line therapy, and progression within 4 weeks after last dose of cetuximab; and prior second-line oxaliplatin- and bevacizumab-based treatment.
Interventions: Biweekly cetuximab, 500 mg/m2, plus irinotecan, 180 mg/m2.
Main Outcomes and Measures: Overall response rate according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival and overall survival and, as an exploratory analysis, RAS mutations in ctDNA.
Results: Twenty-eight patients (9 women and 19 men; median age, 69 years [range, 45-79 years]) were enrolled. Six partial responses (4 confirmed) and 9 disease stabilizations were reported (response rate, 21%; 95% CI, 10%-40%; disease control rate, 54%; 95% CI, 36%-70%). Primary end point was met because lower limit of 95% CI of response rate was higher than 5%. RAS mutations were found in ctDNA collected at rechallenge baseline in 12 of 25 evaluable patients (48%). No RAS mutations were detected in samples from patients who achieved confirmed partial response. Patients with RAS wild-type ctDNA had significantly longer progression-free survival than those with RAS mutated ctDNA (median progression-free survival, 4.0 vs 1.9 months; hazard ratio, 0.44; 95% CI, 0.18-0.98; P = .03).
Conclusions and Relevance: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy. The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients.
Trial Registration: ClinicalTrials.gov Identifier: NCT02296203.
- References:
J Clin Oncol. 2018 Feb 1;36(4):350-358. (PMID: 29215955)
Cancer Med. 2016 Jun;5(6):1204-13. (PMID: 27062580)
Mol Oncol. 2014 Sep 12;8(6):1095-111. (PMID: 25087573)
Lancet Oncol. 2015 Jun;16(6):619-29. (PMID: 25981818)
J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075)
JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714)
Clin Cancer Res. 2015 May 1;21(9):2157-66. (PMID: 25623215)
Biometrics. 1982 Mar;38(1):143-51. (PMID: 7082756)
Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759)
Ann Oncol. 2016 Aug;27(8):1386-422. (PMID: 27380959)
J Natl Cancer Inst. 2015 Nov 12;108(1):. (PMID: 26563355)
Brief Bioinform. 2013 Mar;14(2):178-92. (PMID: 22517427)
N Engl J Med. 2015 May 14;372(20):1909-19. (PMID: 25970050)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Cancer Discov. 2017 Apr;7(4):400-409. (PMID: 28183697)
Cancer Discov. 2016 Feb;6(2):147-153. (PMID: 26644315)
Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843)
Clin Cancer Res. 2017 May 15;23(10):2414-2422. (PMID: 27780856)
J Clin Oncol. 2008 May 10;26(14):2311-9. (PMID: 18390971)
Stat Med. 2001 Mar 30;20(6):859-66. (PMID: 11252008)
J Clin Oncol. 2004 Jan 15;22(2):229-37. (PMID: 14657227)
Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514)
Lancet Oncol. 2016 Jun;17(6):738-746. (PMID: 27108243)
Nat Med. 2015 Jul;21(7):795-801. (PMID: 26030179)
ESMO Open. 2017 Apr 12;2(1):e000147. (PMID: 28761730)
Clin Cancer Res. 2017 Aug 15;23(16):4602-4616. (PMID: 28424201)
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. (PMID: 27899578)
Nature. 2012 Jun 28;486(7404):532-6. (PMID: 22722830)
Br J Cancer. 2017 Jul 25;117(3):347-352. (PMID: 28654634)
JAMA Oncol. 2018 Apr 12;4(4):e175245. (PMID: 29423521)
Nat Commun. 2016 Dec 08;7:13665. (PMID: 27929064)
Ann Oncol. 2017 Dec 1;28(12):3009-3014. (PMID: 29045518)
Ann Oncol. 2012 Sep;23(9):2313-8. (PMID: 22396447)
- Molecular Sequence:
ClinicalTrials.gov NCT02296203
- Accession Number:
0 (Biomarkers, Tumor)
7673326042 (Irinotecan)
EC 2.7.11.1 (BRAF protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
PQX0D8J21J (Cetuximab)
- Publication Date:
Date Created: 20181127 Date Completed: 20191219 Latest Revision: 20200309
- Publication Date:
20240829
- Accession Number:
PMC6439839
- Accession Number:
10.1001/jamaoncol.2018.5080
- Accession Number:
30476968
No Comments.